ArticleBlood2020
A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells.
Article in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Decade-long persistence of CD19 CAR T cells in B cell lymphomas.Nature medicine · 2026Trial
- Viral vector-free generation of orthogonal IL-2-responsive CAR T cells through gene editing of IL-2 and its receptor.Blood immunology & cellular therapy · 2025Article
- Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies.Cancer cell international · 2025Review
- Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks.Nature reviews. Clinical oncology · 2025Review
- Advances in the application of patient-derived xenograft models in acute leukemia resistance.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.Nature medicine · 2024Article
- Emerging Strategies to Overcome Current CAR-T Therapy Dilemmas - Exosomes Derived from CAR-T Cells.International journal of nanomedicine · 2024Review
- Review
- Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL.Frontiers in immunology · 2023Review
- A decade of CD4+ chimeric antigen receptor T-cell evolution in two chronic lymphocytic leukemia patients: were chronic lymphocytic leukemia cells present?Exploration of targeted anti-tumor therapy · 2023Article
- Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells.Nature biomedical engineering · 2022Article
- Application and Design of Switches Used in CAR.Cells · 2022Review
- Review
- Born to survive: how cancer cells resist CAR T cell therapy.Journal of hematology & oncology · 2021Review
- Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects.Acta pharmaceutica Sinica. B · 2021Review
- Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells.Molecular therapy. Methods & clinical development · 2021Article
- Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts.Journal for immunotherapy of cancer · 2021Article
- Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs.Translational oncology · 2021Review
- How metabolism bridles cytotoxic CD8Trends in immunology · 2021Review
- Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.Journal of hematology & oncology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
Unintentional transduction of B-cell acute lymphoblastic leukemia blasts during CART19 manufacturing can lead to CAR19+ leukemic cells (CARB19) that are resistant to CART19 killing. We developed an anti-CAR19 idiotype chimeric antigen receptor (αCAR19) to specifically recognize CAR19+ cells. αCAR19 CAR T cells efficiently lysed CARB19 cells in vitro and in a primary leukemia-derived xenograft model. We further showed that αCAR19-CART cells could be used as an "antidote" to deplete CART19 cells to reduce long-term side effects, such as B-cell aplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.